Company / Cash & Equivalents
ICU Medical Cash & Equivalents History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$308.6M
FY2024
5-year range
$213.0M / $552.8M
FY2020-FY2024
Trend
+21.1%
vs FY2023
Sector context
#65 of 148
Health Care
What the data says
At $309M, ICU Medical's cash & equivalents ranks #65 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 9 years, ranging from $213M in FY2022 to $553M in FY2021.
Based on SEC 10-K filings.
$309M in FY2024 with a 5-year CAGR of +1.2%.
Improved from $213M to $309M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.7%
- 5-Year CAGR
- +1.2%
- 10-Year CAGR
- -
Sector benchmark
#65 of 148 in Health CareTop 44% of 148This company $308.6M Sector average $1.2B
▼
-73.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.2%, indicating consistent growth.
- In FY2024, cash & equivalents increased 21.1% year-over-year.
- Ranks #65 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $308.6M | +21.1% |
| FY2023 | $254.7M | +19.6% |
| FY2022 | $213.0M | -61.5% |
| FY2021 | $552.8M | +60.3% |
| FY2020 | $344.8M | +18.9% |
| FY2019 | $290.1M | -34.8% |
| FY2018 | $445.1M | +32.4% |
| FY2017 | $336.2M | +21.9% |
| FY2016 | $275.8M | +22.0% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026